Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494796 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7PDE4ASSTR4 | |
| SCHEMBL22510132 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7SSTR4HSD11B1 | |
| SCHEMBL19493139 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7PDE4ASSTR4 | |
| SCHEMBL2392859 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7HDAC1SSTR4 | |
| SCHEMBL477032 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7PDE4ASSTR4 | |
| SCHEMBL24244798 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7PDE4ASSTR4 | |
| SCHEMBL6842146 | 0.75 | MKNK1 (0.49) | MKNK1DYRK1AKLK7PDE4ASSTR4 | |
| Hydrochloric Acid SCHEMBL16324142 | 0.73 | MKNK1 (0.51) | MKNK1DYRK1AKLK7HDAC1SSTR4 | |
| SCHEMBL22369939 | 0.72 | MKNK1 (0.46) | MKNK1DYRK1AKLK7 | |
| SCHEMBL21103954 | 0.72 | MKNK1 (0.46) | MKNK1DYRK1AKLK7PDE4ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220185817-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | US | disclosed |
| WO-2021048567-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| CN-111004240-B | Synthetic method of ponatinib intermediate 3-ethynylimidazo [1,2-b ] pyridazine | 山东铂源药业有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20200123165-A1 | KINASE INHIBITORS | INSILICO MEDICINE LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
| CN-111004240-A | Synthetic method of ponatinib intermediate 3-ethynylimidazo [1,2-b ] pyridazine | 山东铂源药业有限公司 | 2020-04-14 | — | — | CN | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| WO-2015143012-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015051244-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2013154878-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | MKNK1 25/4885DYRK1A 822/4885KLK7 4048/4885 |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | MKNK1 3140/4885DYRK1A 2164/4885KLK7 3521/4885 |
| US-20220185817-A1 | IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | MKNK1 344/4885DYRK1A 2486/4885KLK7 3286/4885 |
| US-20200123165-A1 | KINASE INHIBITORS | DDR1, DDR2, DDRGK1 | MKNK1 225/4885DYRK1A 22/4885KLK7 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.